skip to Main Content

Rucaparib Induces Response in BRCA-Mutated Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Some patients with advanced pancreatic cancer who harbor BRCA1 or BRCA2 mutations derived clinical benefit from rucaparib, according to study results.

Rucaparib (Rubraca, Clovis Oncology) — a PARP inhibitor approved by FDA for maintenance treatment of certain women with ovarian, fallopian tube or primary peritoneal cancers — also exhibited a tolerable safety profile. Read more . . . 

Back To Top